News

CCP-08 is the third extended-release product being developed for Vernalis by Tris Pharma ("Tris") for the US prescription cough-cold market.  The first product, Tuzistra XR was approved by the FDA in April 2015 and was

BioInvent president and CEO Michael Oredsson said: “The agreement with Alligator to manufacture its new bispecific antibody ADC-1015 speaks to our leading expertise when it comes to manufacturing of antibodies.

Pfizer said that the S-TRAC study was the first RCC trial of a tyrosine kinase inhibitor (TKI) to extend DFS in the adjuvant setting. The adjuvant therapy intends

The project, using Midatech’s platform gold nanoparticle technology, will focus on developing tolerogenic mechanisms that dampen unwanted autoimmune responses to normal healthy cells in the pancreas, thus preserving

Under the agreement, Sprint Bioscience licenses a PIP4k2a inhibitor program targeting tumor metabolism to the Company. Subsequently, the Company will have full control over further development and worldwide

The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen. Juno has proposed to the FDA

The study’s objective was to investigate the safety and efficacy of several dose regimens for vobarilizumab monotherapy to support additional clinical development. Its primary endpoint was the proportion

The Egality trial focused on patients with moderate-to-severe chronic plaque-type psoriasis. The European Medicines Agency and the US Food and Drug Administration accepted for regulatory review of Sandoz

The companies will use avelumab, a PD-L1 checkpoint inhibitor, together with a platinum-based chemotherapy for women with locally advanced or metastatic disease with earlier untreated epithelial ovarian cancer.